Charles Flexner

Q: What Schools Are Affiliated With Charles Flexner

Charles Flexner is affiliated with the following schools: University of Alabama, Johns Hopkins University, Massachusetts General Hospital

Charles Flexner's AcademicInfluence.com Rankings

Charles Flexner

Medical

#516

World Rank

#700

Historical Rank

Pharmacology

#441

World Rank

#495

Historical Rank

medical Degrees

Charles Flexner

Philosophy

#10061

World Rank

#13755

Historical Rank

Logic

#7001

World Rank

#8600

Historical Rank

philosophy Degrees

Download Badge

Medical
Philosophy

Why Is Charles Flexner Influential?

(Suggest an Edit or Addition)

According to Wikipedia, Charles Williams Flexner is an American physician, clinical pharmaceutical scientist, academic, author and researcher. He is a Professor of Medicine at the Johns Hopkins University School of Medicine.

(See a Problem?)

Charles Flexner's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy (1999) (2106)
HIV-protease inhibitors. (1998) (580)
Pharmacokinetics and Safety of AMD-3100, a Novel Antagonist of the CXCR-4 Chemokine Receptor, in Human Volunteers (2000) (513)
The effect of systemically administered recombinant human nerve growth factor in healthy human subjects (1994) (391)
Intermittent HIV-1 viremia (Blips) and drug resistance in patients receiving HAART. (2005) (389)
Safety, Pharmacokinetics, and Antiviral Activity of AMD3100, a Selective CXCR4 Receptor Inhibitor, in HIV-1 Infection (2004) (353)
HIV drug development: the next 25 years (2007) (298)
Chemotherapy for human immunodeficiency virus-associated non-Hodgkin's lymphoma in combination with highly active antiretroviral therapy. (2001) (287)
HIV-1 reverse transcriptase is a target for cytotoxic T lymphocytes in infected individuals. (1988) (264)
Long-term culture and fine specificity of human cytotoxic T-lymphocyte clones reactive with human immunodeficiency virus type 1. (1989) (250)
Phase 2 study of the safety and efficacy of vicriviroc, a CCR5 inhibitor, in HIV-1-Infected, treatment-experienced patients: AIDS clinical trials group 5211. (2007) (249)
Oral antibiotic treatment of right-sided staphylococcal endocarditis in injection drug users: prospective randomized comparison with parenteral therapy. (1996) (244)
Quantitative Deep Sequencing Reveals Dynamic HIV-1 Escape and Large Population Shifts during CCR5 Antagonist Therapy In Vivo (2009) (239)
Suppression of Preadipocyte Differentiation and Promotion of Adipocyte Death by HIV Protease Inhibitors* (2000) (231)
Prevention of vaccinia virus infection in imiminodeficient mice by vector-directed IL-2 expression (1987) (217)
Vaccinia virus expression vectors. (1987) (191)
Vancomycin-resistant and vancomycin-susceptible enterococcal bacteremia: comparison of clinical features and outcomes. (1998) (191)
HIV type 1 chemokine coreceptor use among antiretroviral-experienced patients screened for a clinical trial of a CCR5 inhibitor: AIDS Clinical Trial Group A5211. (2007) (191)
Updated guideline to perform therapeutic drug monitoring for antiretroviral agents. (2006) (161)
Safety, Tolerability, and Pharmacokinetics of the HIV Integrase Inhibitor Dolutegravir Given Twice Daily With Rifampin or Once Daily With Rifabutin: Results of a Phase 1 Study Among Healthy Subjects (2013) (158)
Drug interactions in patients infected with human immunodeficiency virus. (1996) (152)
Pharmacokinetics, toxicity, and activity of intravenous dextran sulfate in human immunodeficiency virus infection (1991) (141)
Sporadic Urban Leptospirosis (1996) (139)
Dextran sulfate is poorly absorbed after oral administration. (1989) (125)
Efficacy and Safety of Three Antiretroviral Regimens for Initial Treatment of HIV-1: A Randomized Clinical Trial in Diverse Multinational Settings (2012) (125)
In Vivo Emergence of Vicriviroc Resistance in a Human Immunodeficiency Virus Type 1 Subtype C-Infected Subject (2008) (124)
Effect of indomethacin and aspirin on gastric blood flow and acid secretion. (1977) (122)
A prospective, randomized trial examining the efficacy and safety of clarithromycin in combination with ethambutol, rifabutin, or both for the treatment of disseminated Mycobacterium avium complex disease in persons with acquired immunodeficiency syndrome. (2003) (121)
Marked intraindividual variability in antiretroviral concentrations may limit the utility of therapeutic drug monitoring. (2006) (119)
Multiple-Dose Escalation Study of the Safety, Pharmacokinetics, and Biologic Activity of Oral AMD070, a Selective CXCR4 Receptor Inhibitor, in Human Subjects (2007) (117)
The effects of rifampin and rifabutin on the pharmacokinetics and pharmacodynamics of a combination oral contraceptive (1999) (113)
Dual protease inhibitor therapy in HIV-infected patients: pharmacologic rationale and clinical benefits. (2000) (111)
Use of antineoplastic agents in patients with cancer who have HIV/AIDS. (2011) (107)
Interactions between natural health products and antiretroviral drugs: pharmacokinetic and pharmacodynamic effects. (2006) (104)
Non-Hodgkin's lymphoma in patients with advanced HIV infection treated with zidovudine. (1991) (101)
Drug interactions involving combination antiretroviral therapy and other anti-infective agents: repercussions for resource-limited countries. (2008) (90)
Direct-acting antiviral agents for hepatitis C virus infection. (2013) (90)
Protease Inhibitors in AIDS Therapy (2001) (88)
Long-acting parenteral nanoformulated antiretroviral therapy: interest and attitudes of HIV-infected patients. (2013) (85)
Relationship between plasma concentrations of 3'-deoxy-3'-fluorothymidine (alovudine) and antiretroviral activity in two concentration-controlled trials. (1994) (82)
Current Status and Future Prospects of Therapeutic Drug Monitoring and Applied Clinical Pharmacology in Antiretroviral Therapy (2005) (80)
An epitope in human immunodeficiency virus 1 reverse transcriptase recognized by both mouse and human cytotoxic T lymphocytes. (1990) (79)
The transition to dolutegravir and other new antiretrovirals in low-income and middle-income countries: what are the issues? (2018) (79)
Alcohol use and HIV pharmacotherapy. (2002) (73)
Directly administered antiretroviral therapy in the treatment of HIV infection: benefit or burden? (2002) (72)
Long-Acting HIV Drugs for Treatment and Prevention. (2019) (72)
Physiologically Based Pharmacokinetic Modelling to Inform Development of Intramuscular Long-Acting Nanoformulations for HIV (2015) (72)
The Pharmacology of Antiretroviral Nucleoside and Nucleotide Reverse Transcriptase Inhibitors: Implications for Once-Daily Dosing (2005) (71)
Characterization of human immunodeficiency virus gag/pol gene products expressed by recombinant vaccinia viruses. (1988) (68)
Differential Effects of Tipranavir plus Ritonavir on Atorvastatin or Rosuvastatin Pharmacokinetics in Healthy Volunteers (2009) (68)
Safety, Tolerability, and Pharmacokinetic Interactions of the Antituberculous Agent TMC207 (Bedaquiline) With Efavirenz in Healthy Volunteers: AIDS Clinical Trials Group Study A5267 (2012) (68)
Response to vicriviroc in treatment-experienced subjects, as determined by an enhanced-sensitivity coreceptor tropism assay: reanalysis of AIDS clinical trials group A5211. (2009) (64)
Therapeutic Drug Monitoring and Drug–Drug Interactions Involving Antiretroviral Drugs (2005) (61)
Repeated Administration of High-Dose Intermittent Rifapentine Reduces Rifapentine and Moxifloxacin Plasma Concentrations (2008) (60)
Differential effects of p-glycoprotein and multidrug resistance protein-1 on productive human immunodeficiency virus infection. (2002) (58)
Effect of Ritonavir/Saquinavir on Stereoselective Pharmacokinetics of Methadone: Results of AIDS Clinical Trials Group (ACTG) 401 (2001) (58)
Three distinct phases of HIV-1 RNA decay in treatment-naive patients receiving raltegravir-based antiretroviral therapy: ACTG A5248. (2013) (56)
Mutations of the Human Immunodeficiency Virus Type 1 p6Gag Domain Result in Reduced Retention of Pol Proteins during Virus Assembly (1998) (53)
Modified directly observed antiretroviral therapy compared with self-administered therapy in treatment-naive HIV-1-infected patients: a randomized trial. (2009) (52)
Anchor sequence-dependent endogenous processing of human immunodeficiency virus 1 envelope glycoprotein gp160 for CD4+ T cell recognition (1990) (50)
Comparison of once-daily versus twice-daily combination antiretroviral therapy in treatment-naive patients: results of AIDS clinical trials group (ACTG) A5073, a 48-week randomized controlled trial. (2010) (50)
High-dose pentoxifylline in patients with AIDS: inhibition of tumor necrosis factor production. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group. (1995) (50)
Possible Differential Induction of Phase 2 Enzyme and Antioxidant Pathways by American Ginseng, Panax quinquefolius (2008) (49)
Successful vaccination with a polyvalent live vector despite existing immunity to an expressed antigen (1988) (45)
Steady‐state pharmacokinetic interaction of modified‐dose indinavir and rifabutin (2003) (44)
Racial differences in response to antiretroviral therapy for HIV infection: an AIDS clinical trials group (ACTG) study analysis. (2013) (43)
Optimising the manufacture, formulation, and dose of antiretroviral drugs for more cost-efficient delivery in resource-limited settings: a consensus statement. (2012) (43)
Prostaglandin and histamine involvement in the gastric vasodilator action of pentagastrin. (1977) (42)
Balancing Justice and Autonomy in Clinical Research With Healthy Volunteers (2007) (41)
Slow efavirenz metabolism genotype is common in Botswana. (2008) (40)
Antiretroviral implants for treatment and prevention of HIV infection (2018) (39)
The critical need for alternative antiretroviral formulations, and obstacles to their development. (2011) (38)
Rifampicin effect on intracellular and plasma pharmacokinetics of tenofovir alafenamide. (2019) (38)
Emerging antiretroviral drug interactions. (2011) (37)
Recommendations for the Management of Drug–Drug Interactions Between the COVID‐19 Antiviral Nirmatrelvir/Ritonavir (Paxlovid) and Comedications (2022) (37)
Phase I/II study of the toxicity, pharmacokinetics, and activity of the HIV protease inhibitor SC-52151. (1997) (36)
Diarrhea-associated HIV-1 APIs potentiate muscarinic activation of Cl- secretion by T84 cells via prolongation of cytosolic Ca2+ signaling. (2004) (36)
LONG-ACTING DRUGS AND FORMULATIONS FOR THE TREATMENT AND PREVENTION OF HIV. (2020) (35)
Interest of Youth Living With HIV in Long-Acting Antiretrovirals (2019) (35)
Drug delivery strategies and systems for HIV/AIDS pre-exposure prophylaxis and treatment. (2015) (35)
Age-related changes in plasma concentrations of the HIV protease inhibitor lopinavir. (2010) (34)
Pharmacokinetic and metabolic effects of American ginseng (Panax quinquefolius) in healthy volunteers receiving the HIV protease inhibitor indinavir (2008) (34)
The Effect of Chloroquine on Immune Activation and Interferon Signatures Associated with HIV-1. (2016) (32)
Predicting Drug–Drug Interactions Between Rifampicin and Long-Acting Cabotegravir and Rilpivirine Using Physiologically Based Pharmacokinetic Modeling (2019) (31)
A randomized trial of the activity and safety of Ro 24-7429 (Tat antagonist) versus nucleoside for human immunodeficiency virus infection. The AIDS Clinical Trials Group 213 Team. (1995) (31)
Biphasic Elimination of Tenofovir Diphosphate and Nonlinear Pharmacokinetics of Zidovudine Triphosphate in a Microdosing Study (2012) (31)
Attenuation and immunogenicity in primates of vaccinia virus recombinants expressing human interleukin-2. (1990) (31)
Factors Associated With CD8+ T-Cell Activation in HIV-1–Infected Patients on Long-term Antiretroviral Therapy (2014) (29)
Pharmacokinetic Modeling of Plasma and Intracellular Concentrations of Raltegravir in Healthy Volunteers (2011) (29)
The antiretroviral drug pipeline: prospects and implications for future treatment research (2013) (29)
Long-acting implants to treat and prevent HIV infection. (2019) (28)
Semi-solid prodrug nanoparticles for long-acting delivery of water-soluble antiretroviral drugs within combination HIV therapies (2019) (28)
Universal antiretroviral regimens: thinking beyond one-pill-once-a-day (2017) (27)
Activity, safety, and immunological effects of hydroxyurea added to didanosine in antiretroviral-naive and experienced HIV type 1-infected subjects: a randomized, placebo-controlled trial, ACTG 307. (2004) (27)
Long-acting formulations for the treatment of latent tuberculous infection: opportunities and challenges. (2018) (27)
Payment to Healthy Volunteers in Clinical Research: The Research Subject's Perspective (2010) (27)
Compatibility of next-generation first-line antiretrovirals with rifampicin-based antituberculosis therapy in resource limited settings (2017) (27)
Three-Year Safety and Efficacy of Vicriviroc, a CCR5 Antagonist, in HIV-1–Infected Treatment-Experienced Patients (2010) (26)
Alcohol use can result in enhanced drug metabolism in HIV pharmacotherapy. (2001) (26)
Repeated hospitalization for diabetic ketoacidosis. The game of "Sartoris". (1984) (25)
Roles of vaccinia virus in the development of new vaccines. (1988) (25)
Modelling the intradermal delivery of microneedle array patches for long-acting antiretrovirals using PBPK. (2019) (24)
Effect of simultaneous versus staggered dosing on pharmacokinetic interactions of protease inhibitors (2003) (24)
Pharmacokinetic parameters of protease inhibitors and the Cmin/IC50 ratio: call for consensus. (2001) (23)
The challenge of polypharmacy in an aging population and implications for future antiretroviral therapy development. (2017) (23)
Creating demand for long-acting formulations for the treatment and prevention of HIV, tuberculosis, and viral hepatitis (2019) (22)
3-deaza-adenosine and inhibition of HIV (1992) (22)
CHEMOTHERAPY FOR HIV-ASSOCIATED NON-HODGKIN LYMPHOMA (HIV-NHL) IN COMBINATION WITH HIGHLY ACTIVE ANTIRETROVIRAL THERAPY (HAART) IS NOT ASSOCIATED WITH EXCESSIVE TOXICITY. (1999) (22)
Comparison of Human Immunodeficiency Virus Type 1 Pr55Gag and Pr160Gag-Pol Processing Intermediates That Accumulate in Primary and Transformed Cells Treated with Peptidic and Nonpeptidic Protease Inhibitors (2000) (22)
Forecast for the Physician Payment Sunshine Act: Partly to Mostly Cloudy? (2014) (22)
Effect of ritonavir/saquinavir on stereoselective pharmacokinetics of methadone: results of AIDS Clinical Trials Group (ACTG) 401. (2001) (21)
Combination antiretroviral therapy for HIV infection. (1998) (21)
Effect of Low-Dose Ritonavir on the Pharmacokinetics of the CXCR4 Antagonist AMD070 in Healthy Volunteers (2008) (21)
Model-based analysis of the pharmacokinetic interactions between ritonavir, nelfinavir, and saquinavir after simultaneous and staggered oral administration. (2002) (21)
Unexpected drug-drug interactions in human immunodeficiency virus (HIV) therapy: induction of UGT1A1 and bile efflux transporters by Efavirenz. (2012) (21)
In Silico Dose Prediction for Long-Acting Rilpivirine and Cabotegravir Administration to Children and Adolescents (2018) (20)
Toward Consensus on Correct Interpretation of Protein Binding in Plasma and Other Biological Matrices for COVID‐19 Therapeutic Development (2020) (20)
Simultaneous determination of raltegravir and raltegravir glucuronide in human plasma by liquid chromatography-tandem mass spectrometric method. (2011) (20)
HIV genotype and phenotype--arresting resistance? (2000) (20)
Randomized Trial of Ruxolitinib in Antiretroviral-Treated Adults with HIV. (2021) (19)
The potential role of long-acting injectable cabotegravir–rilpivirine in the treatment of HIV in sub-Saharan Africa: a modelling analysis (2021) (18)
Simplification of Antiretroviral Therapy: A Necessary Step in the Public Health Response to HIV/AIDS in Resource-Limited Settings (2014) (18)
Lymphoma diagnosis and plasma Epstein-Barr virus load during vicriviroc therapy: results of the AIDS Clinical Trials Group A5211. (2009) (18)
High-Dose Lopinavir/Ritonavir in Highly Treatment-Experienced HIV-1 Patients: Efficacy, Safety, and Predictors of Response (2007) (18)
(3R, 9R, 10R)-Panaxytriol: A molecular-based nutraceutical with possible application to cancer prevention and treatment. (2008) (17)
Long-acting or extended-release antiretroviral products for HIV treatment and prevention in infants, children, adolescents, and pregnant and breastfeeding women: knowledge gaps and research priorities (2019) (17)
Clearance of recombinant vaccinia virus expressing IL-2: role of local host immune responses. (1993) (17)
Addressing the global burden of hepatitis B virus while developing long-acting injectables for the prevention and treatment of HIV. (2019) (17)
Induction of chemoprotective phase 2 enzymes by ginseng and its components. (2009) (16)
Advances in HIV pharmacology: protein binding, pharmacogenomics, and therapeutic drug monitoring. (2003) (16)
Harnessing nanostructured systems for improved treatment and prevention of HIV disease (2018) (15)
Modelling the long-acting administration of anti-tuberculosis agents using PBPK: a proof of concept study. (2018) (14)
Prescribing Nirmatrelvir–Ritonavir: How to Recognize and Manage Drug–Drug Interactions (2022) (14)
Rhesus monkey macrophages infected with simian immunodeficiency virus cause rapid lysis of CD4-bearing lymphocytes. (1991) (14)
Population pharmacokinetic drug-drug interaction pooled analysis of existing data for rifabutin and HIV PIs. (2016) (13)
Beneficial Pharmacokinetic Interaction Between Atazanavir and Lopinavir/Ritonavir (2007) (12)
Concentration-targeted therapy and the future of HIV management. (2002) (12)
Safety , Tolerability , and Pharmacokinetic Interactions of the Antituberculous Agent TMC 207 ( Bedaquiline ) With Efavirenz in Healthy Volunteers : AIDS Clinical Trials Group Study A 5267 (2012) (12)
Effect of dipyridamole on zidovudine pharmacokinetics and short-term tolerance in asymptomatic human immunodeficiency virus-infected subjects (1994) (12)
Vaccinia Virus Expression Vectors a (1989) (11)
Pharmacokinetics of Darunavir at 900 Milligrams and Ritonavir at 100 Milligrams Once Daily when Coadministered with Efavirenz at 600 Milligrams Once Daily in Healthy Volunteers (2010) (11)
Pharmacoecology: A New Name for an Old Science (2008) (11)
Simplifying antiretroviral therapy. (2004) (11)
Modern Human Immunodeficiency Virus Therapy: Progress and Prospects (2018) (11)
Optimization and simplification of antiretroviral therapy for adults and children (2013) (11)
Severe neutropenia among healthy volunteers given rifabutin in clinical trials (2003) (10)
New approaches to vaccination. (1990) (10)
Darunavir/ritonavir and efavirenz exert differential effects on MRP1 transporter expression and function in healthy volunteers (2010) (10)
HIV Cure: Knocking on the Door (2013) (9)
Drug development strategies for salvage therapy: conflicts and solutions. (2006) (9)
Erratum: HIV type 1 chemokine co-receptor use among antiretroviral- experienced patients screened for a clinical trial of a CCR5 inhibitor: AIDS Clinical Trial Group A5211 (Clinical Infectious Diseases (2007) 44, (591-595)) (2007) (9)
Pharmacokinetic/Pharmacodynamic Modeling of the Antiretroviral Activity of the CCR5 Antagonist Vicriviroc in Treatment Experienced HIV-Infected Subjects (ACTG Protocol 5211) (2010) (9)
Allogeneic bone marrow transplantation with post-transplant cyclophosphamide for patients with HIV and haematological malignancies: a feasibility study. (2020) (9)
Safety, Tolerability, and Antiretroviral Effects of Ritonavir‐Nelfinavir Combination Therapy Administered for 48 Weeks (2000) (9)
Accelerator Mass Spectrometry Measurement of Intracellular Concentrations of Active Drug Metabolites in Human Target Cells In Vivo (2010) (8)
Amprenavir and Lopinavir Pharmacokinetics following Coadministration of Amprenavir or Fosamprenavir with Lopinavir/Ritonavir, with or without Efavirenz (2007) (8)
Assessing Human Immunodeficiency Virus Type 1 Tropism: Comparison of Assays Using Replication-Competent Virus versus Plasma-Derived Pseudotyped Virions (2009) (8)
Inactivation of human immunodeficiency virus type 1 reverse transcriptase by oltipraz: evidence for the formation of a stable adduct. (1995) (7)
Human erythrocytes bearing electroinserted CD4 neutralize infection in vitro by primary isolates of human immunodeficiency virus type 1. (1996) (6)
Effect of hydroxyurea and dideoxyinosine on intracellular 3'-deoxyadenosine-5'-triphosphate concentrations in HIV-infected patients. (2007) (6)
Principles of clinical pharmacology in postexposure prophylaxis. (1997) (6)
Post-exposure prophylaxis revisited: new CDC guidelines. Centers for Disease Control and Prevention. (1998) (5)
Why a universal antiretroviral regimen? (2017) (5)
HIV INFECTIONS AND AIDS (2009) (5)
HIV-related drug metabolism and cytochrome P450 enzymes. (2000) (5)
Effect of Antiretroviral Therapy on Plasma Concentrations of Chloroquine and Desethyl-chloroquine (2018) (5)
Herbal Remedies in Resource‐poor Settings: Friend or Foe? (2008) (5)
Predicting Pharmacokinetics of a Tenofovir Alafenamide Subcutaneous Implant Using Physiologically Based Pharmacokinetic Modelling (2020) (5)
Impact of long-acting therapies on the global HIV epidemic. (2021) (5)
Diagnosis of human immunodeficiency virus infection using citrated whole blood (1997) (4)
Anhydrous nanoprecipitation for the preparation of nanodispersions of tenofovir disoproxil fumarate in oils as candidate long-acting injectable depot formulations (2019) (4)
Safety, tolerability, and antiretroviral effects of ritonavir-nelfinavir combination therapy administered for 48 weeks. (2000) (4)
Ageing in patients with chronic HIV infection: impact of hypercoagulation (2018) (4)
Active Learning Centre: potential uses and efficacy of an interactive Internet-based teaching tool (2000) (4)
Genes, ethnicity, and efavirenz response: clinical pharmacology update from the 11th CROI. (2004) (4)
Treatment optimization: an outline for future success. (2013) (4)
Effect of Low-Dose Ritonavir on the Pharmacokinetics of the CXCR 4 Antagonist AMD 070 in Healthy Volunteers † (2008) (4)
When a Serious Adverse Event in Research Occurs, How Do Other Volunteers React? (2011) (3)
Dose Optimization of Hydroxychloroquine for Coronavirus Infection 2019: Do Blood Concentrations Matter? (2020) (3)
HLA B57 and abacavir hypersensitivity. (2002) (3)
Predicted effects of the introduction of long-acting injectable cabotegravir pre-exposure prophylaxis in sub-Saharan Africa: a modelling study. (2023) (3)
Supramolecular nanomedicines through rational design of self-assembling prodrugs. (2022) (3)
The future of long-acting agents for preexposure prophylaxis (2022) (3)
Progress in pharmacology and drug interactions from the 10th CROI. (2003) (3)
New antiretroviral agents in clinical development (1992) (3)
Leveraging the therapeutic, biological, and self-assembling potential of peptides for the treatment of viral infections. (2022) (2)
Psychological Distress and Physical Pain Appear To Have No Short-Term Adverse Impact on Plasma HIV-1 RNA Levels in Patients on Successful HAART (2005) (2)
Complications of HIV therapy. (2000) (2)
Preferences of Persons with or at Risk for Hepatitis C for Long-Acting Treatments. (2021) (2)
Erratum: Multiple-dose escalation study of the safety, pharmacokinetics, and biologic activity of oral AMD070, a selective CXCR4 receptor inhibitor, in human subjects (Antimicrobial Agents and Chemotherapy (2007) 51, 7, (2351-2358)) (2007) (2)
Pharmacology at the 12th CROI: generic antiretrovirals, drug interactions, and therapeutic drug monitoring. (2005) (1)
Report from Boston: the 12th Conference on Retroviruses and Opportunistic Infections (CROI). New drugs, new targets: good news on the horizon. (2005) (1)
Pharmacokinetics of Darunavir 900mg and Ritonavir 100mg Once Daily when Co (2010) (1)
XEN and the Art of Pharmacology: Learning from an Old Science (2004) (1)
Pharmacokinetics of Ruxolitinib in HIV Suppressed Individuals on Antiretroviral Agent Therapy from the ACTG A5336 Study (2021) (1)
Patients, physicians, and clinical trials: the other side of the coins. (1999) (1)
Intravenous dextran sulfate (DS) increases circulating HIV antigen levels in patients with ARC or AIDS (1991) (1)
What's in a trough? Therapeutic drug monitoring and antiretroviral regimens. (2000) (1)
Erratum: Marked intraindividual variability in antiretrovrial concentrations may limit the utility of therapeutic drug monitoring (Clinical Infectious Diseases (April 15, 2006) 42 (1189-1196)) (2006) (1)
IQs, VIQs, and NIQs: are we smart yet? (2002) (1)
Our Students, Our Selves (2009) (1)
Chapter 13 – Pharmacology of antiretroviral drugs (2012) (1)
Pharmacology of Antiretroviral Drugs (2008) (1)
Comparison of the effects of 3'-azidothymidine with those of neutralizing antibodies on simian immunodeficiency virus infection in macrophages (1993) (1)
HIV Pharmacology-What's New? (2005) (0)
Chemotherapy f or H uman I mmunodeficiency Virus-Associated N on-Hodgkin's L ymphoma i n Combination W ith H ighly A ctive A ntiretroviral T herapy (2001) (0)
Cytokine production and fever with chimeric toxins (1996) (0)
The future of HIV treatment: I left my HAART in the 20th century. (2001) (0)
Double jeopardy: the hazards of drug-drug interactions. (1998) (0)
Transdermal delivery with microneedle patches using in silico modelling (2017) (0)
Reply to Srinivas (2009) (0)
IL-6 blockade with tocilizumab diminishes indices of inflammation that are linked to mortality in treated HIV infection. (2023) (0)
Pharmacology: a progress report. (1999) (0)
Effect of Low-Dose Ritonavir on the Pharmacokinetics of the CXCR4 Antagonist AMD070 in Healthy Volunteers (cid:1) † (2008) (0)
Pharmacology and drug interactions: a progress report. (2002) (0)
Principles of clinical pharmacology in postexposure prophylaxis. Discussion (1997) (0)
Comparison of Amprenavir Concentrations Following Administration of Amprenavir / Ritonavir or Amprenavir / Lopinavir / Ritonavir (2005) (0)
When will once (-a day) be enough? (2000) (0)
HIV-1 protease inhibitors potentiate muscarinic stimulation of Cl− secretion in association with increased and prolonged Ca2+ entry in T84 cells (2003) (0)
The pharmacokinetic profiles of some dual protease inhibitor regimens support further investigation of once-daily dosing (0)
Editorial: New drugs for HIV: quo vadis? (2022) (0)
Dose selection for rifabutin in combination with HIV-protease inhibitors (2016) (0)
What Clinicians Need to Know About the Development of Long-Acting Formulations. (2022) (0)
Multiple-Dose Escalation Study of the Safety, Pharmacokinetics, and Biologic Activity of Oral AMD070, a Selective CXCR4 Receptor Inhibitor, in Human Subjects (2007) (0)
Pharmacology and drug interactions: compartmentalizing antiretrovirals. (2000) (0)
Drug interactions and pharmacology. (2000) (0)
Indomethacin, pentagastrin and gastric arterial blood flow (1976) (0)
Simulation of long-acting administration of antituberculosis agents using pharmacokinetic modelling (2016) (0)
Towards a Unifying Theory of Clinical Research (2009) (0)
Survival kinetics of autologous erythrocytes (RBCs) modified by electroinsertion of recombinant CD4 (1997) (0)
OPINION Optimization and simplification of antiretroviral therapy for adults and children (2013) (0)
Pharmacology in Paris. (2003) (0)
Discussion: What are the optimal regimens for postexposure chemoprophylaxis? (1997) (0)
Internal medicine: cyclosporine-a powerful new immunosuppressant. (1985) (0)
The HIV-1 protease inhibitor nelfinvir enhances CA++-dependent Cl- secretion in intestinal T84 cell monolayers (2000) (0)
In praise of descriptive nomenclature (1996) (0)
The LEAP Process: Streamlining the Development of Long-Acting Products and Formulations for Infectious Diseases. (2022) (0)
Antiviral Supramolecular Polymeric Hydrogels by Self-Assembly of Tenofovir-Bearing Peptide Amphiphiles (2022) (0)
Safety of optimized antiretroviral therapy during allogeneic matched and haploidentical bone marrow transplant in HIV+ individuals (2015) (0)
Transitioning Long-Acting Products to a Generic Marketplace: What's Missing? (2022) (0)
Allogeneic Bone Marrow Transplant for HIV Patients with Hematologic Malignancies with Post-transplant Cyclophosphamide: a Feasibility Study (2020) (0)
Discussion: Zidovudine toxicity in uninfected healthcare workers (1997) (0)
Semi-solid prodrug nanoparticles for long-acting delivery of water-soluble antiretroviral drugs within combination HIV therapies (2019) (0)
Development of Prodrug Approaches for Long‐Acting Nanoformulations of Emtricitabine‐Based Regimens (2018) (0)
The Changing Face of HIV (2008) (0)
New drugs: attacking chemokine receptors. (2002) (0)
Multi-scale system pharmacology modelling pipeline to assess the prophylactic efficacy of NRTIs against HIV-1 Mr (2016) (0)
Fat city: understanding HIV lipodystrophy. (1998) (0)
Update from the 6th International Workshop on the Clinical Pharmacology of HIV Therapy: new drugs, new formulations and drug interactions. (2005) (0)
Long-acting injectable formulations for children and adolescents using PBPK modelling (2016) (0)
More from CROI...new drugs: full pipeline, steady progress. (2003) (0)
Preliminary safety and activity evaluation of new agents for the treatment of HIV-1 infection: Recommended guidelines for trial design (1992) (0)
Rationale for testing chemokine inhibitors (Virustats) for prevention of HIV-1 transmission. (2001) (0)
macrophages. virus infection in with those of neutralizing antibodies on simian Comparison of the effects of 3'-azidothymidine (2013) (0)
Drug transporter, drug concentrations, and drug interactions. (2001) (0)
In Vivo Emergence of Vicriviroc Resistance in a Human Immunodeﬁciency Virus Type 1 Subtype C-Infected Subject (cid:1) † (2008) (0)
Practice point 45 – Drug interactions in HIV and AIDS (2010) (0)
Dose Optimization of Hydroxychloroquine for COVID-19: Do Blood Concentrations Matter? (2020) (0)

This paper list is powered by the following services:

Other Resources About Charles Flexner

en.wikipedia.org

What Schools Are Affiliated With Charles Flexner?

Charles Flexner is affiliated with the following schools:

Charles Flexner's Academic­Influence.com Rankings

Why Is Charles Flexner Influential?

Charles Flexner's Published Works

Published Works

Other Resources About Charles Flexner

What Schools Are Affiliated With Charles Flexner?

Charles Flexner's AcademicInfluence.com Rankings